Fluciclovine-PET/CT for Bone Metastases From Prostate Adenocarcinoma
| Status: | Recruiting |
|---|---|
| Conditions: | Prostate Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 9/13/2018 |
| Start Date: | April 15, 2018 |
| End Date: | November 2021 |
| Contact: | Carol Stuehm |
| Email: | carols@email.arizona.edu |
| Phone: | 5206268318 |
A Pilot Study of F-18 Fluciclovine-PET/CT as A Diagnostic Tool for Bone Metastases in Patients With Hormonal Sensitive and Resistant Prostate Adenocarcinoma
Determine diagnostic accuracy of Axumin-PET positive bone lesion by confirmatory bone biopsy.
Inclusion Criteria:
1. Male
2. Be ≥ 18 years of age
3. Diagnosed with prostate cancer
4. Be willing and able to provide informed consent
5. Be informed of the investigational nature of this study
Exclusion Criteria:
1. Having a history of severe claustrophobia
2. Weight exceeding 400lbs
We found this trial at
1
site
University of Arizona The University of Arizona is a premier, public research university. Established in...
Click here to add this to my saved trials
